← Back to all trials
Completed
NCT07936942
Quality of Life and Uremic Toxins in HDx
Conditions: End Stage Kidney Disease (ESKD)
Sex: All
Healthy volunteers: No
Phase: NA
Enrollment: 23
Sponsor: Mackay Memorial Hospital
Location: MacKay Memorial Hospital Taipei
Summary
Expanded hemodialysis (HDx) is a dialysis treatment designed to improve the removal of certain waste products from the blood. However, its effects on health-related quality of life and blood levels of uremic toxins in patients receiving long-term hemodialysis remain uncertain.
This study aimed to evaluate changes in quality of life and uremic toxin levels after switching from conventional hemodialysis to HDx. Patients who had been receiving maintenance hemodialysis for at least 10 years underwent HDx for three months. Quality of life and blood levels of selected uremic toxins were assessed before and after the treatment period.
The study aimed to determine whether switching to HDx was associated with changes in patients' quality of life and uremic toxin profiles.
Eligibility Criteria
Inclusion Criteria:
* Adults aged 18 years or older.
* Patients receiving maintenance hemodialysis three times weekly for at least 10 years.
* Ability to provide written informed consent.
Exclusion Criteria:
* Active malignancy.
* Other major organ failure.
* History of major surgery within the preceding 3 months.
Source: ClinicalTrials.gov (NCT07936942). StuddyBuddy aggregates publicly available trial information.